Valproic acid protects against haemorrhagic shock-induced signalling changes via PPARγ activation in an in vitro model

British Journal of Pharmacology

Volumn 172, Issue 22, 2015, Pages 5306-5317

  Zuckermann, Alexandra M E ^a   La Ragione, Roberto M ^b   Baines, Deborah L ^c   Williams, Robin S B ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; BETA CATENIN; CIGLITAZONE; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; VALPROIC ACID; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; LACTATE DEHYDROGENASE; PROTECTIVE AGENT;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HEMORRHAGIC SHOCK; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPERCAPNIA; HYPOTHERMIA; HYPOXIA; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AGONISTS; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; HYPERCAPNIA; HYPOTHERMIA; HYPOXIA; L-LACTATE DEHYDROGENASE; PHOSPHORYLATION; PPAR GAMMA; PROTECTIVE AGENTS; RNA, SMALL INTERFERING; SHOCK, HEMORRHAGIC; SIGNAL TRANSDUCTION; VALPROIC ACID;

EID: 84956713795     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13320     Document Type: Article

References (67)

1. Abdelrahman M, Collin M, Thiemermann C, (2004). The peroxisome proliferator-activated receptor-γ ligand 15-deoxyd12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock. Shock 22: 555-561.
2. Abu Aboud O, Wettersten HI, Weiss RH, (2013). Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One 8: 1-9.
3. Alam HB, Shuja F, Butt MU, Duggan M, Li Y, Zacharias N, et al., (2009). Surviving blood loss without blood transfusion in a swine poly-trauma model. Surgery 146: 325-333.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013a). The concise guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013b). The concise guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
6. An Z, Muthusami S, Yu JR, Park WY, (2014). T0070907, a PPAR γ inhibitor induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe. Reprod Sci 21: 1352-1361.
7. Angele MK, Schneider CP, Chaudry IH, (2008). Bench-to-bedside review: latest results in hemorrhagic shock. Crit Care 12: 218.
8. Bialer M, (1991). Clinical pharmacology of valpromide. Clin Pharmacokinet 20: 114-122.
9. Bialer M, Yagen B, (2007). Valproic acid: second generation. Neurotherapeutics 4: 130-137.
10. Berger SL, (2002). Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12: 142-148.
11. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC, (2002). Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 277: 33791-33798.
12. Chang P, Orabi B, Deranieh R, Dham M, Hoeller O, Shimshoni J, et al., (2012). The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis Model Mech 5: 115-124.
13. Chang P, Terbach N, Plant N, Chen PE, Walker MC, Williams RSB, (2013). Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology 69: 105-114.
14. Chang P, Walker MC, Williams RSB, (2014). Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid. Neurobiol Dis 62: 296-306.
15. Chang P, Zuckermann AME, Williams S, Close AJ, Cano-Jaimez M, Mcevoy JP, et al., (2015). Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency. J Pharmacol Exp Ther 352: 43-52.
16. Chen G, Huang LD, Jiang YM, Manji HK, (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
17. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S, (1998). Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 95: 11211-11216.
18. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA, (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
19. DSM IV (2000). American Psychiatric Association: Diagnostic and statistical manual of mental disorders. American Psychiatric Association: Washington DC.
20. Eikel D, Lampen A, Nau H, (2006). Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem Res Toxicol 19: 272-278.
21. Eldar-Finkelman H, Krebs EG, (1997). Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci U S A 94: 9660-9664.
22. Elphick LM, Pawolleck N, Guschina IA, Chaieb L, Eikel D, Nau H, et al., (2012). Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds. Dis Model Mech 5: 231-240.
23. Frey KP, Egleston BL, Salkever DS, Scharfstein DO, (2006). A national evaluation of the effect of trauma-center care on mortality. N Engl J Med 354: 366-378.
24. Gotfryd K1, Skladchikova G, Lepekhin EA, Berezin V, Bock E, Walmod PS, (2010). Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation. BMC Cancer 10: 383.
25. Gregersen N, Mortensen PB, Kølvraa S, (1983). On the biologic origin of C6-C10-dicarboxylic and C6-C10-omega-1-hydroxy monocarboxylic acids in human and rat with acyl-CoA dehydrogenation deficiencies: in vitro studies on the omega- and omega-1-oxidation of medium-chain (C6-C12) fatty acids in human and rat liver. Pediatr Res 17: 828-834.
26. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al., (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
27. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS, (2004). Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086.
28. Gutierrez G, Reines HD, Wulf-Gutierrez ME, (2004). Clinical review: hemorrhagic shock. Crit Care 8: 373-381.
29. Hall AC, Brennan A, Goold RG, Cleverly K, Lucas FR, Gordon-Weeks PR, et al., (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 20: 257-270.
30. Hanada M, Feng J, Hemmings BA, (2004). Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697: 3-16.
31. Hooper C, Killick R, Lovestone S, (2008). The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-1439.
32. Hotter G, Palacios L, Sola A, (2004). Low O2 and high CO2 in LLC-PK1 cells culture mimics renal ischemia-induced apoptosis. Lab Investig 84: 213-220.
33. Hughes SD, Kanabus M, Anderson G, Hargreaves IP, Rutherford T, O'Donnell M, et al., (2014). The ketogenic diet component decanoic acid increases mitochondrial citrate synthase and complex I activity in neuronal cells. J Neurochem 129: 426-433.
34. Hwabejire JO, Lu J, Liu B, Li Y, Halaweish I, Alam HB, (2014). Valproic acid for the treatment of hemorrhagic shock: a dose-optimization study. J Surg Res 186: 363-370.
35. Isoherranen N, Yagen B, Bialer M, (2003). New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol 16: 203-211.
36. Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK, et al., (2010). Valproic acid use in pregnancy and congenital malformations. N Engl J Med 363: 2185-2193.
37. Jope RS, Yuskaitis CJ, Beurel E, (2007). Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res 32: 577-595.
38. Kauvar DS, Wade CE, (2005). The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care 9: S1-9.
39. Kauvar DS, Lefering R, Wade CE, (2006). Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma 60: S3-11.
40. Keller ME, Aihara R, LaMorte WW, Hirsch EF, (2003). Organ-specific changes in high-energy phosphates after hemorrhagic shock and resuscitation in the rat. J Am Coll Surg 196: 685-690.
41. Kheirbek T, Kochanek AR, Alam HB, (2009). Hypothermia in bleeding trauma: a friend or a foe? Scand J Trauma Resusc Emerg Med 17: 65.
42. Kitagishi Y, Matsuda S, (2013). Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute to neuroprotection in a traumatic brain injury. Alzheimers Res Ther 5: 42.
43. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM, (1995). A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813-819.
44. Kota BP, Huang THW, Roufogalis BD, (2005). An overview on biological mechanisms of PPARs. Pharmacol Res 51: 85-94.
45. Lampen A, Siehler S, Ellerbeck U, Goettlicher M, Nau H, (1999). New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor δ (PPARδ). Toxicol Appl Pharmacol 160: 238-249.
46. Lampen A, Carlberg C, Nau H, (2001). Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives. Eur J Pharmacol 431: 25-33.
47. Lecky FE, Woodford M, Bouamra O, Yates DW, (2002). Trauma Audit and Research Network. Lack of change in trauma care in England and Wales since 1994. Emerg Med J 19: 520-523.
48. Li Y, Liu B, Sailhamer EA, Yuan Z, Shults C, Velmahos GC, et al., (2008). Cell protective mechanism of valproic acid in lethal hemorrhagic shock. Surgery 144: 217-224.
49. Palaty J, Abbott FS, (1995). Structure-activity relationships of unsaturated analogs of valproic acid. J Med Chem 38: 3398-3406.
50. Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, et al., (2010). Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-β/δ antagonist GSK3787. Mol Pharmacol 78: 419-430.
51. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH, (2001). Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768.
52. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-106.
53. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS, (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
54. Rossaint R, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Gordini G, et al., (2006). Key issues in advanced bleeding care in trauma. Shock 26: 322-331.
55. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P, (1996). Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272: 1023-1026.
56. Ryves W, Dalton EC, Harwood AJ, Williams RSB, (2005). GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 7: 260-265.
57. Sakanaka C, (2002). Phosphorylation and regulation of β-catenin by casein kinase Iε. J Biochem 132: 697-703.
58. Shults C, Sailhamer EA, Li Y, Liu B, Tabbara M, Butt MU, et al., (2008). Surviving blood loss without fluid resuscitation. J Trauma 64: 629-638.
59. Shoemaker WC, (1996). Oxygen Transport and Oxygen Metabolism in Shock and Critical Illness. Crit Care Clin 12: 939-969.
60. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, et al., (1999). PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 96: 6199-6204.
61. Terbach N, Williams RSB, (2009). Structure-function studies for the panacea, valproic acid. Biochem Soc Trans 37: 1126-1132.
62. Tomson T, Battino D, (2008). Teratogenic effects of antiepileptic drugs. Seizure 17: 166-171.
63. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, et al., (2003). Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308: 990-994.
64. Valvezan AJ, Klein PS, (2012). GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front Mol Neurosci 5: 1-13.
65. Williams RSB, Cheng L, Mudge AW, Harwood AJ, (2002). A common mechanism of action for three mood-stabilizing drugs. Nature 417: 292-295.
66. Xu X, Müller-Taubenberger A, Adley KE, Pawolleck N, Lee VWY, Wiedemann C, et al., (2007). Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid. Eukaryot Cell 6: 899-906.
67. Zacharias N, Sailhamer EA, Li Y, Liu B, Butt MU, Shuja F, et al., (2011). Histone deacetylase inhibitors prevent apoptosis following lethal hemorrhagic shock in rodent kidney cells. Resuscitation 82: 105-109.